Full text is available at the source.
Abstract
Diabetic kidney disease (DKD) is a major contributor to end-stage renal disease (ESRD) globally, highlighting the importance of inflammation in its development.
- Chronic inflammation plays a critical role in the pathogenesis of DKD, shifting the focus from traditional metabolic and hemodynamic factors.
- Recent advances identify various inflammatory mechanisms involved in DKD, including the activation of inflammatory pathways and impaired cellular functions.
- Emerging diagnostic biomarkers are being developed through omics technologies and artificial intelligence to improve the identification of DKD.
- Therapeutic strategies focusing on inflammation include sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), which have shown renal benefits.
- A multifaceted approach integrating multi-omics data and combined therapies may enhance the management of DKD.
Simplified